Compare IDEXX Laboratories, Inc. (IDXX) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs UiPath Inc — how do they compare? IDEXX Laboratories, Inc. trades at $512.76 (market cap $39.92B), while UiPath Inc trades at $13.26 (market cap $6.81B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.9× UiPath Inc's market cap, and UiPath Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and UiPath Inc for 139 Days on average.
| IDXX | PATH | |
|---|---|---|
Market Cap | $39.92B | $6.81B |
Volume | 715,982 | 22,766,109 |
Sector | Health | Technology |
52-Week High | $766.68 | $19.29 |
52-Week Low | $504.70 | $9.38 |
Typical Hold Time | 46 Days | 139 Days |
Enterprise Value | $40.82B | $5.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, down 0.44% with bearish technical signals despite strong fundamentals. The company demonstrates robust revenue growth, expanding from $3.4B in 2022 to $4.3B in 2025, with net income reaching $1.06B. Recent acquisitions like CoVetAI and diagnostic platform expansions highlight strategic growth initiatives. Technical indicators show oversold conditions with RSI at 26.58, while moving averages signal bearish momentum. Analyst consensus remains optimistic with a $665 price target representing 30% upside potential.
The outlook remains positive given strong earnings beats, expanding profit margins, and strategic acquisitions. However, risks include technical weakness, FX headwinds, and competitive pressures. With 56.5% analyst buy ratings and institutional accumulation, IDXX offers growth potential but requires monitoring of technical support levels near $492-$502 for entry opportunities.
UiPath (PATH) trades at $13.25, up 1.15% with mixed technical signals showing bearish momentum but neutral oscillators. The company demonstrates improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though the stock faces near-term headwinds from valuation concerns and competitive pressures.
PATH presents a turnaround story with strong revenue growth and path to profitability, but faces execution risks amid competitive automation landscape. The consensus price target of $15.13 suggests 14% upside potential, though technical weakness and mixed analyst sentiment warrant caution. Key catalysts include AI platform adoption and enterprise expansion, while risks involve growth sustainability and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
